Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma
Abstract Anti-programmed cell death-1 (anti-PD-1) therapies have shown a favorable efficacy and good tolerance for relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). However, there are limited data on long-term outcomes among patients with r/r cHL who achieve an objective response to ant...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2023-09-01
|
| Series: | Signal Transduction and Targeted Therapy |
| Online Access: | https://doi.org/10.1038/s41392-023-01600-7 |
| _version_ | 1797556102799294464 |
|---|---|
| author | Weiping Liu Ningjing Lin Xinqin Feng Yan Xie Chong You Xiaohua Zhou Yuqin Song Jun Zhu |
| author_facet | Weiping Liu Ningjing Lin Xinqin Feng Yan Xie Chong You Xiaohua Zhou Yuqin Song Jun Zhu |
| author_sort | Weiping Liu |
| collection | DOAJ |
| description | Abstract Anti-programmed cell death-1 (anti-PD-1) therapies have shown a favorable efficacy and good tolerance for relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). However, there are limited data on long-term outcomes among patients with r/r cHL who achieve an objective response to anti-PD-1 therapies. A total of 260 responders from four, phase 2 clinical trials were included in this study. The median age was 32 years with a male/female ratio of 1.3:1. After a median follow-up period of 31.1 months, 116 (44.6%) responders experienced disease progression and 18 (6.9%) died. The 3-year progression-free survival (PFS) and overall survival (OS) rates were 55.1% and 89.7% overall. Patients with partial remission (PR) had inferior outcomes compared with those who achieved complete remission (3-year PFS, 29.5% vs. 72.3%, P < 0.001; 3-year OS, 81.5% vs. 94.4%, P = 0.017). Moreover, the survival outcome was inferior for patients with refractory disease compared with those with relapsed disease. Multivariate Cox regression analysis showed PR and refractory disease were independent risk factors for PFS. In conclusion, PR and refractory disease have a negative impact on the survival benefit of anti-PD-1 therapeutics in patients with r/r cHL, which highlights the need for multimodal treatment strategies. |
| first_indexed | 2024-03-10T16:58:07Z |
| format | Article |
| id | doaj.art-863e73c0555f444fb157805503b93229 |
| institution | Directory Open Access Journal |
| issn | 2059-3635 |
| language | English |
| last_indexed | 2024-03-10T16:58:07Z |
| publishDate | 2023-09-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Signal Transduction and Targeted Therapy |
| spelling | doaj.art-863e73c0555f444fb157805503b932292023-11-20T11:04:37ZengNature Publishing GroupSignal Transduction and Targeted Therapy2059-36352023-09-01811710.1038/s41392-023-01600-7Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphomaWeiping Liu0Ningjing Lin1Xinqin Feng2Yan Xie3Chong You4Xiaohua Zhou5Yuqin Song6Jun Zhu7Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & InstituteKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & InstituteSchool of Mathematical Sciences, Peking UniversityKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & InstituteBeijing International Center for Mathematical Research, Peking UniversityBeijing International Center for Mathematical Research, Peking UniversityKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & InstituteKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & InstituteAbstract Anti-programmed cell death-1 (anti-PD-1) therapies have shown a favorable efficacy and good tolerance for relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). However, there are limited data on long-term outcomes among patients with r/r cHL who achieve an objective response to anti-PD-1 therapies. A total of 260 responders from four, phase 2 clinical trials were included in this study. The median age was 32 years with a male/female ratio of 1.3:1. After a median follow-up period of 31.1 months, 116 (44.6%) responders experienced disease progression and 18 (6.9%) died. The 3-year progression-free survival (PFS) and overall survival (OS) rates were 55.1% and 89.7% overall. Patients with partial remission (PR) had inferior outcomes compared with those who achieved complete remission (3-year PFS, 29.5% vs. 72.3%, P < 0.001; 3-year OS, 81.5% vs. 94.4%, P = 0.017). Moreover, the survival outcome was inferior for patients with refractory disease compared with those with relapsed disease. Multivariate Cox regression analysis showed PR and refractory disease were independent risk factors for PFS. In conclusion, PR and refractory disease have a negative impact on the survival benefit of anti-PD-1 therapeutics in patients with r/r cHL, which highlights the need for multimodal treatment strategies.https://doi.org/10.1038/s41392-023-01600-7 |
| spellingShingle | Weiping Liu Ningjing Lin Xinqin Feng Yan Xie Chong You Xiaohua Zhou Yuqin Song Jun Zhu Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma Signal Transduction and Targeted Therapy |
| title | Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma |
| title_full | Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma |
| title_fullStr | Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma |
| title_full_unstemmed | Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma |
| title_short | Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma |
| title_sort | long term survival benefit of anti pd 1 therapy in patients with relapsed or refractory classical hodgkin lymphoma |
| url | https://doi.org/10.1038/s41392-023-01600-7 |
| work_keys_str_mv | AT weipingliu longtermsurvivalbenefitofantipd1therapyinpatientswithrelapsedorrefractoryclassicalhodgkinlymphoma AT ningjinglin longtermsurvivalbenefitofantipd1therapyinpatientswithrelapsedorrefractoryclassicalhodgkinlymphoma AT xinqinfeng longtermsurvivalbenefitofantipd1therapyinpatientswithrelapsedorrefractoryclassicalhodgkinlymphoma AT yanxie longtermsurvivalbenefitofantipd1therapyinpatientswithrelapsedorrefractoryclassicalhodgkinlymphoma AT chongyou longtermsurvivalbenefitofantipd1therapyinpatientswithrelapsedorrefractoryclassicalhodgkinlymphoma AT xiaohuazhou longtermsurvivalbenefitofantipd1therapyinpatientswithrelapsedorrefractoryclassicalhodgkinlymphoma AT yuqinsong longtermsurvivalbenefitofantipd1therapyinpatientswithrelapsedorrefractoryclassicalhodgkinlymphoma AT junzhu longtermsurvivalbenefitofantipd1therapyinpatientswithrelapsedorrefractoryclassicalhodgkinlymphoma |